1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines
Key Takeaways
Cervical oncogenesis is driven primarily by persistent infection with high-risk HPV (hrHPV) genotypes 16 and 18, which encode viral oncoproteins E6 and E7 that degrade p53 and inactivate retinoblastoma protein (pRb), respectively.
Routine cervical cancer screening begins at age 21 with cytology every 3 years; co-testing is not used before 30 because transient HPV infection is common, although ACS and ACOG accept primary hrHPV testing every 5 years from age 25.
For women aged 30 to 65, the final USPSTF (2018) statement accepts primary hrHPV every 5 years, co-testing every 5 years, or cytology every 3 years; ACS (2020) and the 2024 USPSTF draft prefer primary hrHPV, and the draft accepts patient-collected samples.
Screening may cease at age 65 if the patient has adequate negative prior screening (3 consecutive negative cytology or 2 negative co-tests within 10 years, with the most recent within 5 years) and no history of CIN 2+ within the past 25 years.
The 2019 ASCCP Consensus Guidelines dictate management based on personalized risk thresholds for immediate CIN 3+: ≥60% warrants expedited treatment, 25%–59% allows expedited treatment or colposcopy, 4.0%–24% mandates colposcopy, and <4.0% indicates clinical surveillance.
Cervical Anatomy & Oncogenic HPV Pathophysiology
The cervix consists of an outer ectocervix (stratified squamous epithelium) and an internal endocervical canal (simple columnar mucus-secreting epithelium), meeting at the squamocolumnar junction (SCJ). Estrogen exposure and vaginal acidity induce squamous metaplasia, forming the transformation zone (TZ). Because immature metaplastic cells are vulnerable to human papillomavirus (HPV) integration, >90% of cervical intraepithelial neoplasia (CIN) and invasive cancers originate here.
High-Risk vs. Low-Risk HPV Genotypes
HPV is a double-stranded DNA virus transmitted via mucosal contact. Over 100 strains exist:
- High-Risk HPV (hrHPV): Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Types 16 and 18 cause ~70% of invasive cervical cancers (HPV 16 causes ~50% of squamous cell carcinomas; HPV 18 causes ~50% of cervical adenocarcinomas).
- Low-Risk HPV: Types 6 and 11 are non-oncogenic, causing >90% of condylomata acuminata and benign low-grade lesions.
Molecular Oncogenesis: E6 and E7 Oncoproteins
Viral integration disrupts the viral E2 repressor, causing persistent transcription of E6 and E7:
- E6 oncoprotein: Binds tumor suppressor p53 and mediates ubiquitin-proteasomal degradation, abolishing p53-dependent DNA repair and apoptosis.
- E7 oncoprotein: Binds retinoblastoma protein (pRb), displacing E2F transcription factors and driving unregulated G1/S cell cycle progression.
Cervical Cancer Screening Guidelines
Protocols from USPSTF, ACOG, and ACS balance cancer detection against overdiagnosis:
| Age Cohort | USPSTF & ACOG Guidelines | ACS Recommendations (2020) | Clinical Rationale |
|---|---|---|---|
| < 21 Years | No screening, regardless of sexual coitus initiation. | No screening | Up to 90% of adolescent HPV infections clear within 24 months; excisional therapy causes cervical stenosis and preterm labor. |
| 21–29 Years | Cytology alone every 3 years. No co-testing; ACOG accepts primary hrHPV every 5 years from age 25. | Primary hrHPV every 5 years starting at age 25. | High transient HPV prevalence causes excessive false-positive rates for primary HPV screening in women in their 20s. |
| 30–65 Years | Three acceptable options (USPSTF 2018 final): 1. Primary hrHPV alone every 5 years; 2. Co-testing (cytology + hrHPV) every 5 years; 3. Cytology alone every 3 years. The 2024 USPSTF draft favors primary hrHPV, clinician- or patient-collected. | Primary hrHPV alone every 5 years (preferred). If unavailable, co-testing q5y or cytology q3y. | Primary hrHPV has higher sensitivity for CIN 3+ than cytology alone, providing superior long-term reassurance after a negative test. |
| > 65 Years | Discontinue screening if adequate negative prior screening criteria are met and no CIN 2+ history. | Discontinue screening if criteria met. | Incidence of new oncogenic infections declines; postmenopausal atrophy increases false-positive cytology. |
Note
The FDA approved self-collected vaginal samples for HPV testing in a health care setting in 2024 and an at-home collection device in 2025. Self-collection suits primary hrHPV screening (not cytology), and a positive result still needs clinician follow-up.
Screening Cessation Criteria at Age 65
Discontinue screening at age 65 only with documented adequate negative prior screening:
- Three consecutive negative cytology results within the past 10 years, OR
- Two consecutive negative co-tests or negative primary hrHPV tests within 10 years, with the most recent test within 5 years.
- No CIN 2+ history: Patients with treated CIN 2, CIN 3, or AIS must continue routine screening for at least 25 years post-treatment, even beyond age 65.
Special Populations
- Immunocompromised Patients (HIV, organ transplant, systemic lupus): Screen at HIV diagnosis or sexual onset (starting by age 21). In patients with HIV, obtain cytology at diagnosis and then annually; after 3 consecutive normal annual results, screen every 3 years for life. Co-testing is permitted at age 30+. Screening continues beyond age 65.
- In Utero DES Exposure: Annual cytology combined with visual and digital inspection of the entire vaginal vault to detect clear cell adenocarcinoma.
- Post-Hysterectomy with Cervix Removed (for Benign Disease): Discontinue screening; vaginal cuff cytology is not indicated. If the cervix was retained (supracervical hysterectomy), continue routine screening. If hysterectomy was performed for CIN 2+, continue vaginal cuff screening for 25 years.
2019 ASCCP Risk-Based Management Guidelines
The 2019 ASCCP Guidelines use personalized risk estimation. Management compares a patient's immediate risk and 5-year risk of CIN 3+ against clinical action thresholds ("Equal Management for Equal Risk"):
| Immediate CIN 3+ Risk | ASCCP Management Directive | Representative Clinical Scenarios |
|---|---|---|
| ≥ 60% | Expedited treatment (LEEP/conization) preferred; colposcopy acceptable. | HPV 16-positive with HSIL cytology in patients aged ≥25 with incomplete past screening. |
| 25% to 59% | Expedited treatment or colposcopy acceptable. | HSIL cytology with any hrHPV positive, or HPV 16+ with ASC-H cytology. |
| 4.0% to 24% | Diagnostic colposcopy recommended. | ASC-US with hrHPV positive (risk ~4.5%); LSIL with hrHPV positive or unknown; Persistent hrHPV positive with normal cytology |
| < 4.0% | Surveillance recommended (Colposcopy deferred): | |
| 5-yr risk ≥ 0.55% | • 1-year repeat surveillance: Co-test in 12 months. | hrHPV positive with normal cytology, negative HPV 16/18 genotyping. |
| 5-yr risk 0.15%–0.54% | • 3-year repeat surveillance: Repeat screening in 3 years. | ASC-US with negative hrHPV, or normal cytology with negative prior screening. |
| 5-yr risk < 0.15% | • 5-year routine return: Standard population screening. | Negative primary hrHPV or negative co-test with negative history. |
Important
Expedited treatment without preliminary biopsy is contraindicated in pregnancy, patients planning future childbearing where cervical incompetence is a concern, and patients under age 25.
Management of Specific Cytologic Abnormalities
- ASC-US: Reflex hrHPV testing is preferred. If hrHPV is positive (immediate risk ~4.5%), perform diagnostic colposcopy. If hrHPV is negative, resume screening in 3 years. In patients aged 21–24, repeat cytology alone at 12 months.
- LSIL: In women aged 25+, colposcopy is indicated if hrHPV is positive or unknown. If hrHPV is negative, repeat co-testing in 1 year. In women aged 21–24, repeat cytology at 12 months is preferred.
- ASC-H: Immediate colposcopy is mandatory in all age groups regardless of HPV status (CIN 2+ risk 20%–50%).
- HSIL: Immediate CIN 3+ risk >25%. In nonpregnant patients aged ≥25, expedited treatment (LEEP) or colposcopy is acceptable; expedited treatment is preferred if HPV 16 is positive.
- Atypical Glandular Cells (AGC): High risk for invasive adenocarcinoma of cervix, endometrium, fallopian tubes, or ovaries. Workup requires diagnostic colposcopy with endocervical curettage (ECC). In addition, endometrial biopsy (EMB) is mandatory in:
- All patients aged 35 and older with AGC
- Patients under 35 with endometrial cancer risk factors (abnormal bleeding, obesity, PCOS, nulliparity)
- Atypical Endometrial Cells: Primary workup is diagnostic endometrial biopsy and endocervical curettage, alongside colposcopy.
A 32-year-old female presents to the clinic for follow-up of her cervical cancer screening results. Her liquid-based cytology demonstrates Atypical Squamous Cells of Undetermined Significance (ASC-US). Reflex high-risk HPV (hrHPV) testing is positive for non-16/18 oncogenic subtypes. Her past screening history 3 years ago was normal cytology. According to the 2019 ASCCP Risk-Based Management Guidelines, what is the most appropriate next step in clinical management?
Repeat cervical cytology and hrHPV co-testing in 12 months.
Perform diagnostic colposcopy with directed biopsies as indicated.
Proceed directly to loop electrosurgical excision procedure (LEEP) without colposcopy.
Order pelvic ultrasonography and endometrial biopsy.
A 42-year-old multigravida presents with cervical cytology showing Atypical Glandular Cells, Not Otherwise Specified (AGC-NOS). She has normal, regular menses and reports no postcoital bleeding, pelvic pain, or abnormal discharge. Her body mass index is 24 kg/m². What is the most appropriate initial diagnostic evaluation for this patient?
Diagnostic colposcopy alone with endocervical curettage deferred unless a lesion is visualized.
Repeat cytology in 6 months combined with high-risk HPV testing.
Colposcopy with endocervical curettage (ECC) AND an endometrial biopsy.
Total abdominal hysterectomy and bilateral salpingectomy.
A 66-year-old female presents for a routine annual preventive visit. Her surgical history is notable for a total abdominal hysterectomy with bilateral salpingo-oophorectomy performed 12 years ago for symptomatic uterine leiomyomas. Histopathological evaluation at the time of surgery confirmed benign leiomyomas with an entirely normal cervix. Her medical records document normal cervical cytology tests every 3 years for 15 years prior to surgery. What is the recommended cervical and vaginal cancer screening plan for this patient?
Discontinue routine screening; vaginal cuff cytology is not indicated.
Perform vaginal cuff cytology every 3 years until age 75.
Obtain high-risk HPV testing of the vaginal cuff every 5 years lifelong.
Perform an annual bimanual pelvic examination and screening pelvic ultrasound.
Sections you finish are checked off in the contents.